利妥昔单抗治疗系统性硬化症相关间质性肺病：评 Yoo 等人的文章。
Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.
出版信息
Rheumatol Int. 2011 Jun;31(6):841-2. doi: 10.1007/s00296-010-1485-3. Epub 2010 Apr 8.
PMID:20376665
Abstract
Several lines of evidence from basic research indicate that B cells may contribute to the pathogenesis of systemic sclerosis. Clinical studies as well have provided preliminary data pointing to the direction that B-cell depletion with rituximab might be a therapeutic option for patients with this debilitating disease.
摘要
多项基础研究的结果表明，B 细胞可能与系统性硬化症的发病机制有关。临床研究也提供了初步数据，表明利妥昔单抗（一种针对 B 细胞的单克隆抗体）清除 B 细胞可能是治疗这种使人衰弱的疾病的一种选择。
Zotero 插件